-- Robert Preidt
SUNDAY, Aug. 17, 2014 (HealthDay News) -- A drug used to treat a
rare type of bone marrow cancer restores hair in patients with an
autoimmune disease that causes hair loss, a new study found.
Columbia University Medical Center researchers found that the
drug ruxolitinib (brand name: Jakafi) restored hair growth in a
small number of patients with alopecia areata, a disease in which
immune cells destroy hair follicles.
Alopecia areata can occur at any age and affects men and women.
Patients typically lose patches of hair on the scalp, but may also
lose facial and body hair. Currently, there are no known treatments
to completely restore hair in these patients, who can suffer mental
and emotional stress, the researchers said.
First, the researchers identified the immune cells that destroy
hair follicles in people with alopecia areata. They also discovered
that ruxolitinib -- which is approved by the U.S. Food and Drug
Administration to treat a bone marrow cancer called myelofibrosis
-- eliminated these immune cells.
The study team first tested the drug in mice and then in a small
number of people with moderate to severe alopecia areata (more than
30 percent hair loss). Within five months of starting treatment,
three patients had total hair regrowth.
"We've only begun testing the drug in patients, but if the drug continues to be successful and safe, it will have a dramatic positive impact on the lives of people with this disease," study leader Dr. Raphael Clynes said in a Columbia news release.
"We still need to do more testing to establish that ruxolitinib should be used in alopecia areata, but this is exciting news for patients and their physicians," he added. "This disease has been completely understudied -- until now, only two small clinical trials evaluating targeted therapies in alopecia areata have been performed, largely because of the lack of mechanistic insight into it."
The study findings were published online Aug. 17 in the journal
The American Academy of Dermatology has more about
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.